disitamab vedotin + cisplatin

Disitamab vedotin + cisplatin is a combination therapy under investigation primarily for the treatment of urothelial carcinoma, including muscle-invasive and metastatic forms. Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) that targets human epidermal growth factor receptor 2 (HER2). It consists of a fully humanized anti-HER2 monoclonal antibody linked to monomethyl auristatin E (MMAE), a cytotoxic agent, via a cleavable linker. Upon binding to HER2-expressing tumor cells, the ADC is internalized and MMAE is released intracellularly, disrupting microtubule assembly and inducing cell death. Cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. The combination aims to leverage both targeted cytotoxicity from disitamab vedotin and broad cytotoxic effects from cisplatin. This regimen has been compared with standard gemcitabine-cisplatin chemotherapy in clinical studies for bladder cancer[1][7]. Disitamab vedotin has shown promising efficacy as monotherapy or in combinations, particularly in HER2-positive cancers[3][4][6].